Drug
Deuruxolitinib clinical trials
Also written CTP-543.
Keep track of what changes. Save the Deuruxolitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- CTP-543
- 19
Studies by the year they started
23 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 6 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 0
Concert Pharmaceuticals (19) · Sun Pharmaceutical Industries, Inc. (3) · Sun Pharma Japan Limited (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Deuruxolitinib is read from its arms, and is right about nine times in ten.
Testing it · 23
- Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia AreataRecruitingPhase 3Sun Pharma Japan LimitedNCT07617597Written as Deuruxolitinib
- Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia AreataRecruitingPhase 3Sun Pharmaceutical Industries, Inc.NCT07133308Written as Deuruxolitinib
- European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataCompletedPhase 3Sun Pharmaceutical Industries, Inc.NCT05041803Written as CTP-543
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataActive, not recruitingPhase 2/3Sun Pharmaceutical Industries, Inc.NCT03898479Written as CTP-543
- A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia AreataCompletedPhase 2Concert PharmaceuticalsNCT04784533Written as CTP-543
- Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)CompletedPhase 3Concert PharmaceuticalsNCT04797650Written as CTP-543
- Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)CompletedPhase 3Concert PharmaceuticalsNCT04518995Written as CTP-543
- Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia AreataCompletedPhase 2Concert PharmaceuticalsNCT03941548Written as CTP-543
- Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia AreataCompletedPhase 2Concert PharmaceuticalsNCT03811912Written as CTP-543
- Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543CompletedPhase 1Concert PharmaceuticalsNCT05467722Written as CTP-543
- Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543CompletedPhase 1Concert PharmaceuticalsNCT05468749Written as CTP-543
- Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy SubjectsCompletedPhase 1Concert PharmaceuticalsNCT05478772Written as CTP-543
- Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy VolunteersCompletedPhase 1Concert PharmaceuticalsNCT05467696Written as CTP-543
- Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy SubjectsCompletedPhase 1Concert PharmaceuticalsNCT05467709Written as CTP-543
- Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia AreataCompletedPhase 2Concert PharmaceuticalsNCT03137381Written as CTP-543
- A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health VolunteersCompletedPhase 1Concert PharmaceuticalsNCT05192369Written as CTP-543
- Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult SubjectsCompletedPhase 1Concert PharmaceuticalsNCT04843540Written as CTP-543
- Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult SubjectsCompletedPhase 1Concert PharmaceuticalsNCT04743414Written as CTP-543
- Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female SubjectsCompletedPhase 1Concert PharmaceuticalsNCT04309643Written as CTP-543
- Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male VolunteersCompletedPhase 1Concert PharmaceuticalsNCT04092712Written as [14C]-CTP-543
Codes
What other systems call Deuruxolitinib · ClinicalTrials.gg INT002133
- MeSH (NLM) C000731752DeuruxolitinibOne source NLM
- UNII (FDA) 0CA0VSF91YDEURUXOLITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q123485858deuruxolitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175770DeuruxolitinibOne source FDA
- DrugBank DB18847One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731752 | Deuruxolitinib | One source NLM |
| UNII (FDA) | 0CA0VSF91Y | DEURUXOLITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123485858 | deuruxolitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175770 | Deuruxolitinib | One source FDA |
| DrugBank | DB18847 | — | One source Wikidata |
Also registered as deuruxolitinib phosphate (UNII 8VJ43S4LCM).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.